You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

34 Results
Guidelines and Advice
Status: Current
ID: MCC
Jun 2006
Guidelines and Advice
Status: Archived
ID: 20-1
Aug 2006
Guidelines and Advice
Status: Education and Information
ID: 1-24 Version 2
Version: 2
May 2006
Guidelines and Advice
Status: Archived
ID: CED 3
Jan 2006
Guidelines and Advice
Status: Archived
ID: CED 2
Version: 2
Jan 2006
Guidelines and Advice
Status: Archived
ID: 13-8
Oct 2006
Guidelines and Advice
Status: Archived
ID: HPVTest
Apr 2006
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Statistical Reports
May 2006
Drug
Other Name(s): Xgeva®; Wyost™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages